Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19
Reviews in Medical Virology · 2024
DOI: 10.1002/rmv.2500 ↗At a glance
Übersichtsarbeit in Reviews in Medical Virology, 2024. Written by Aroona Razzaq and 15 co-authors. Institution: Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China. Major MEDLINE topics: COVID-19, ErbB Receptors, Signal Transduction. Cited 14 times so far (Crossref); 130 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously producing new variants, necessitating effective therapeutics. Patients are not only confronted by the immediate symptoms of infection but also by the long‐term health issues linked to long COVID‐19. Activation of epidermal growth factor receptor (EGFR) signalling during SARS‐CoV‐2 infection promotes virus propagation, mucus hyperproduction, and pulmonary fibrosis, and suppresses the host's antiviral response. Over the long term, EGFR activation in COVID‐19, particularly in COVID‐19‐induced pulmonary fibrosis, may be linked to the development of lung cancer. In this review, we have summarised the significance of EGFR signalling in the context of SARS‐CoV‐2 infection. We also discussed the targeting of EGFR signalling as a promising strategy for COVID‐19 treatment and highlighted erlotinib as a superior option among EGFR inhibitors. Erlotinib effectively blocks EGFR and AAK1, thereby preventing SARS‐CoV‐2 replication, reducing mucus hyperproduction, TNF‐α expression, and enhancing the host's antiviral response. Nevertheless, to evaluate the antiviral efficacy of erlotinib, relevant clinical trials involving an appropriate patient population should be designed.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.
- Department of Biology, College of Natural Sciences and Mathematics, Mindanao State University, Marawi City, Philippines.
- Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
- Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.
- Hunan Key Laboratory of Animal Models for Human Diseases, School of Life Sciences, Central South University, Changsha, China.
- Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
ORCID profiles: Zanxian Xia
Cite
APA
Razzaq, A., Disoma, C., Zhou, Y., Tao, S., Chen, Z., Liu, S., Zheng, R., Zhang, Y., Liao, Y., Chen, X., Liu, S., Dong, Z., Xu, L., Deng, X., Li, S., & Xia, Z. (2024). Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19. Reviews in Medical Virology. https://doi.org/10.1002/rmv.2500
Vancouver
Razzaq A, Disoma C, Zhou Y, Tao S, Chen Z, Liu S, et al. Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19. Reviews in Medical Virology. 2024. doi:10.1002/rmv.2500
BibTeX
@article{Razzaq2024,
author = {Razzaq, Aroona and Disoma, Cyrollah and Zhou, Yuzheng and Tao, Siyi and Chen, Zongpeng and Liu, Sixu and Zheng, Rong and Zhang, Yongxing and Liao, Yujie and Chen, Xuan and Liu, Sijie and Dong, Zijun and Xu, Liangtao and Deng, Xu and Li, Shanni and Xia, Zanxian},
title = {Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19},
journal = {Reviews in Medical Virology},
year = {2024},
doi = {10.1002/rmv.2500}
}
EUVIMED